Download Sample
Add to CartGlobal Ovarian Cancer Market Growth, Share, Size, Trends and Forecast (2025 - 2031)
By Type;
Epithelial Ovarian Tumors, Ovarian Germ Cell Tumors, Ovarian Stromal Tumors, and Primary Peritoneal Carcinoma.By Cancer Stage;
Stage I, Stage II, Stage III, and Stage IV.By Diagnostic;
Physical Examination, Biopsy, Blood Tests, Human Chorionic Gonadotropin (HCG) Test, Ultrasound, MRI, PET, and CT scans.By Treatment;
Chemotherapy, Targeted Therapy, Radiation Therapy, Immunotherapy, Hormonal Therapy, and Surgery.By Geography;
North America, Europe, Asia Pacific, Middle East and Africa, and Latin America - Report Timeline (2021 - 2031).Introduction
Global Ovarian Cancer Market (USD Million), 2021 - 2031
In the year 2024, the Global Ovarian Cancer Market was valued at USD 1,945.76 million. The size of this market is expected to increase to USD 3,281.03 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 7.8%.
Ovarian cancer, primarily affecting women, is a significant health concern worldwide. It is the most common type of cancer originating in the ovaries, with three primary types: stromal tumors, epithelial tumors, and germ cell tumors. Each type has distinct characteristics and treatment protocols, making the disease complex and necessitating ongoing research and development in the pharmaceutical sector.
The increasing prevalence of ovarian cancer is a major driver of market growth. As the number of cases rises, so does the demand for effective treatments. Innovations and advancements in the pharmaceutical industry are crucial in addressing this need. The development of new drugs and therapies, backed by extensive research, has led to significant progress in treating ovarian cancer. These advancements include targeted therapies, immunotherapies, and personalized medicine, which offer more effective and less invasive treatment options.
Health-conscious consumers are increasingly aware of the importance of early detection and treatment of cancer. This growing awareness is driving demand for cancer screenings and preventive measures, further fueling market growth. Additionally, the rapid approval of various cancer drugs by regulatory bodies ensures that patients have access to the latest treatments. These expedited approvals are crucial in providing timely interventions that can significantly improve patient outcomes.
The aging population is another critical factor contributing to market growth. With a higher proportion of elderly individuals, the incidence of ovarian cancer is expected to rise, as age is a significant risk factor for the disease. Consequently, there is a growing need for oral drugs that offer convenience and improved adherence to treatment protocols among older patients.
Increased healthcare spending and the availability of medicines also play pivotal roles in market expansion. Governments and private sectors are investing heavily in healthcare infrastructure, making advanced treatments more accessible to a broader population. Improvements in the structure of hospital pharmacies and the availability of cutting-edge therapies enhance the overall quality of care for ovarian cancer patients. However, despite these positive trends, certain challenges could hinder market growth. A significant barrier is the shortage of skilled healthcare professionals who specialize in oncology. The complexity of cancer treatment requires highly trained personnel, and a lack of such professionals can limit the availability and quality of care. Additionally, the high cost of treatment poses a significant challenge. Advanced therapies and drugs, while effective, are often expensive, making them inaccessible to many patients, especially in low-income regions.
Global Ovarian Cancer Market Recent Developments
-
In September 2022, AstraZeneca and Merck announced that Lynparza (olaparib) has been approved in China for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to 1st-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD)-positive status.
-
In September 2022, Pfizer and Strata Oncology have expanded their partnership for a clinical trial assessing various cancer therapies in new, biomarker-guided patient groups.
Segment Analysis
The global ovarian cancer market is segmented by type, cancer stage, diagnostic methods, and treatments. By type, the market includes epithelial ovarian tumors, ovarian germ cell tumors, ovarian stromal tumors, and primary peritoneal carcinoma. Epithelial ovarian tumors are the most common, comprising around 90% of cases, and drive the majority of the market due to their high prevalence. Germ cell tumors, though rarer, are significant due to their occurrence in younger women and the specialized treatment protocols they require. Stromal tumors, also less common, are notable for their hormonal activity and the unique therapeutic approaches they necessitate. Primary peritoneal carcinoma, which mimics ovarian cancer, adds complexity to diagnosis and treatment, further influencing market dynamics. The market is also categorized by cancer stages: Stage I, Stage II, Stage III, and Stage IV. Early stages (I and II) have better prognosis and treatment outcomes, primarily involving surgery and localized therapies. However, the majority of ovarian cancer cases are diagnosed at later stages (III and IV), where the disease has spread beyond the ovaries, necessitating more aggressive treatments like chemotherapy and targeted therapies. These later stages significantly impact market demand for advanced diagnostic tools and treatment options.
Diagnostic methods include physical examinations, biopsies, blood tests, human chorionic gonadotropin (HCG) tests, and imaging techniques such as ultrasound, MRI, PET, and CT scans. Physical examinations and biopsies are initial steps in diagnosis, while blood tests, including markers like CA-125, play crucial roles in monitoring disease progression. Advanced imaging techniques like MRI, PET, and CT scans are essential for accurate staging and treatment planning, driving significant demand within the diagnostic segment. The integration of these diagnostics is vital for early detection and effective management, thereby influencing market growth. Treatment options encompass chemotherapy, targeted therapy, radiation therapy, immunotherapy, hormonal therapy, and surgery. Chemotherapy remains a cornerstone, especially for advanced stages, despite its side effects. Targeted therapies, such as PARP inhibitors, have gained traction due to their ability to attack specific cancer cells while sparing normal cells, thus improving efficacy and reducing adverse effects. Radiation therapy, though less commonly used, is pivotal in certain cases. Immunotherapy and hormonal therapy represent burgeoning fields, with immunotherapy harnessing the body's immune system to fight cancer, and hormonal therapy targeting hormone-driven tumors. Surgery is often the first-line treatment, particularly for early-stage cancers, and includes procedures like hysterectomy and oophorectomy.
Global Ovarian Cancer Segment Analysis
In this report, the Global Ovarian Cancer Market has been segmented by Type, Cancer Stage, Diagnostic, Treatment, and Geography.
Global Ovarian Cancer Market, Segmentation by Type
The Global Ovarian Cancer Market has been segmented by Type into Epithelial Ovarian Tumors, Ovarian Germ Cell Tumors, Ovarian Stromal Tumors, and Primary Peritoneal Carcinoma.
Epithelial ovarian tumors dominate this segment, accounting for approximately 90% of all ovarian cancer cases. These tumors originate from the surface layer of the ovary and are further classified into serous, mucinous, endometrioid, and clear cell carcinomas. The high prevalence of epithelial tumors underscores the need for extensive research and development of targeted therapies and early detection techniques. Advanced diagnostic tools and personalized treatment plans have significantly improved outcomes for patients with epithelial ovarian cancer. Ovarian germ cell tumors, while less common, constitute a critical segment due to their unique occurrence primarily in younger women. These tumors arise from the reproductive cells of the ovary and include types such as dysgerminomas, endodermal sinus tumors, and teratomas. Germ cell tumors often respond well to chemotherapy and have a relatively good prognosis compared to other ovarian cancer types. However, their rarity and the specific demographic they affect necessitate specialized diagnostic and therapeutic approaches, driving innovation in this niche market segment.
Ovarian stromal tumors, also a rarer form, originate from the connective tissue cells that hold the ovary together and produce hormones. This type includes granulosa cell tumors, thecomas, and Sertoli-Leydig cell tumors. These tumors are significant due to their hormonal activity, which can influence the clinical presentation and management of the disease. Hormonal therapies play a crucial role in treating stromal tumors, and ongoing research is focused on understanding their unique pathophysiology to develop more effective treatments. Primary peritoneal carcinoma, though not originating in the ovary, is included in the ovarian cancer segment because it behaves similarly to epithelial ovarian cancer. It arises from the peritoneum, the lining of the abdominal cavity, and shares many characteristics with epithelial ovarian tumors, including symptoms, spread patterns, and treatment responses. The inclusion of primary peritoneal carcinoma in this market segment highlights the need for comprehensive diagnostic criteria and therapeutic strategies that encompass all similar peritoneal malignancies.
Global Ovarian Cancer Market, Segmentation by Cancer Stage
The Global Ovarian Cancer Market has been segmented by Cancer Stage into Stage I, Stage II, Stage III, and Stage IV.
Stage I ovarian cancer, where the disease is confined to one or both ovaries, offers the best prognosis and is often managed with surgery alone, followed by targeted therapies if necessary. The early detection and treatment of Stage I ovarian cancer are crucial, as they significantly increase the chances of successful outcomes and long-term survival, driving demand for effective screening and diagnostic tools. Stage II ovarian cancer indicates that the cancer has spread to other pelvic structures, such as the fallopian tubes, uterus, or other nearby tissues. This stage requires a combination of surgical intervention and chemotherapy to manage the disease. The treatment approach for Stage II ovarian cancer is more aggressive than for Stage I, involving debulking surgery to remove as much of the tumor as possible, followed by chemotherapy to eliminate residual cancer cells. The complexity of treatment at this stage drives the need for advanced therapeutic options and comprehensive care protocols, influencing market growth.
Stage III ovarian cancer is characterized by the spread of cancer outside the pelvis to the lining of the abdomen or to the lymph nodes. This stage is the most common at diagnosis due to the often asymptomatic nature of earlier stages, leading to a higher demand for sophisticated diagnostic imaging technologies such as CT scans, MRI, and PET scans. Treatment for Stage III involves extensive surgery and combination chemotherapy, with the potential inclusion of targeted therapies like PARP inhibitors. The high prevalence and advanced nature of Stage III ovarian cancer necessitate significant healthcare resources and innovative treatment strategies, making it a critical segment in the market. Stage IV ovarian cancer is the most advanced, indicating that the cancer has metastasized to distant organs such as the liver, lungs, or beyond the abdomen. This stage requires the most aggressive and multifaceted treatment approach, including surgery, chemotherapy, targeted therapy, and sometimes radiation therapy. Palliative care also becomes essential to manage symptoms and improve the quality of life for patients. The treatment of Stage IV ovarian cancer is complex and costly, driving demand for cutting-edge therapies and comprehensive patient management systems.
Global Ovarian Cancer Market, Segmentation by Diagnostic
The Global Ovarian Cancer Market has been segmented by Diagnostic into Physical Examination, Biopsy, Blood Tests, Human Chorionic Gonadotropin (HCG) Test, Ultrasound, MRI, PET, and CT scans.
Human Chorionic Gonadotropin (HCG) tests, and various imaging techniques, including ultrasound, MRI, PET, and CT scans. Physical examinations are often the first step in the diagnostic process, where healthcare providers assess symptoms and perform pelvic exams to detect any abnormalities. While initial, these examinations are critical in identifying potential cases early and directing patients to more definitive diagnostic procedures. Biopsies remain the gold standard for confirming ovarian cancer diagnoses. During a biopsy, tissue samples from the ovary or other affected areas are extracted and examined microscopically for cancer cells. This method provides definitive evidence of malignancy and helps in staging the cancer, which is essential for determining the appropriate treatment plan. The precision of biopsy results makes it a cornerstone in ovarian cancer diagnostics.
Blood tests, including the CA-125 test, are vital in monitoring ovarian cancer. Elevated levels of CA-125, a protein found in higher concentrations in ovarian cancer patients, can indicate the presence of the disease and help in tracking treatment response and detecting recurrences. Other blood tests may include markers like HE4, which, when used in conjunction with CA-125, can improve diagnostic accuracy. Although not definitive on their own, blood tests are invaluable for ongoing monitoring and assessment. The Human Chorionic Gonadotropin (HCG) test, typically associated with pregnancy, is also utilized in diagnosing certain types of ovarian germ cell tumors. Elevated HCG levels can signal the presence of these rare tumors, aiding in their identification and differentiation from other ovarian cancer types.
Imaging techniques play a crucial role in diagnosing and staging ovarian cancer. Ultrasound, particularly transvaginal ultrasound, is often used as an initial imaging test to visualize ovarian abnormalities. It provides detailed images of the ovaries and can help distinguish between benign and malignant masses. MRI (Magnetic Resonance Imaging) offers detailed cross-sectional images of the body and is useful in assessing the extent of the disease and its spread to nearby structures. PET (Positron Emission Tomography) scans, often combined with CT (Computed Tomography) scans, provide metabolic and anatomical information, respectively. PET scans highlight areas of high metabolic activity, typical of cancer cells, while CT scans offer detailed images of the internal anatomy. Together, PET and CT scans are instrumental in comprehensive cancer staging, treatment planning, and monitoring response to therapy.
Global Ovarian Cancer Market, Segmentation by Treatment
The Global Ovarian Cancer Market has been segmented by Treatment into Chemotherapy, Targeted Therapy, Radiation Therapy, Immunotherapy, Hormonal Therapy, and Surgery.
Chemotherapy remains the cornerstone of ovarian cancer treatment, particularly for advanced stages. It involves the use of cytotoxic drugs that kill rapidly dividing cancer cells, often administered after surgical debulking. Despite its effectiveness, chemotherapy can cause significant side effects, prompting ongoing research to develop regimens that are both efficacious and better tolerated. Targeted therapy has revolutionized ovarian cancer treatment by focusing on specific molecular targets associated with cancer progression. Drugs like PARP inhibitors (e.g., olaparib, niraparib) are used particularly in patients with BRCA mutations or homologous recombination deficiencies. These therapies offer the advantage of specificity, which reduces damage to normal cells and minimizes side effects compared to traditional chemotherapy. The rise of personalized medicine, where treatment is tailored based on genetic profiling of the tumor, underscores the growing importance of targeted therapies in the ovarian cancer treatment landscape.
Radiation therapy, although less commonly used for ovarian cancer, can be an effective modality in certain scenarios. It employs high-energy radiation to kill cancer cells or shrink tumors, typically used in a palliative setting to alleviate symptoms or in cases where surgery is not feasible. The precise application of radiation therapy can help manage localized disease and improve quality of life for patients. Immunotherapy represents an emerging frontier in ovarian cancer treatment, harnessing the body’s immune system to recognize and attack cancer cells. Checkpoint inhibitors and other immune-modulating drugs are being investigated in clinical trials, showing promise in improving outcomes for patients with resistant or recurrent ovarian cancer. Immunotherapy's potential for long-term remission makes it a highly anticipated addition to the treatment arsenal. Hormonal therapy, particularly relevant for certain ovarian stromal tumors, involves the use of medications that alter hormone levels to inhibit cancer growth. While not as widely applicable as other treatments, hormonal therapy can be a vital option for specific patient subsets, providing a less aggressive alternative with fewer side effects.
Global Ovarian Cancer Market, Segmentation by Geography
In this report, the Global Ovarian Cancer Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.
Global Ovarian Cancer Market Share (%), by Geographical Region, 2024
The major countries covered in the global ovarian cancer market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Asia-Pacific is expected to have the highest market growth due to the presence of key generic pharmaceuticals companies in this region and rise in government initiatives and special communities. North America dominates the market due to the increase in women population as the disease tends to affect to women and large availability of treatment options.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Market Trends
This report provides an in depth analysis of various factors that impact the dynamics of Global Ovarian Cancer Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.
Drivers, Restraints and Opportunity Analysis
Drivers
- Increase in Elderly Population
-
Rising Demand for Oral Drugs- Oral cancer drugs offer numerous advantages over traditional intravenous (IV) therapies, contributing to their increasing popularity among patients and healthcare providers. One of the primary benefits of oral drugs is convenience. Patients can take these medications at home, reducing the need for frequent hospital visits or prolonged stays at healthcare facilities for IV administration. This not only enhances the quality of life for patients, who can maintain a more normal daily routine, but also alleviates the burden on healthcare systems, allowing resources to be allocated more efficiently.
Oral drugs also support better treatment adherence. Patients are more likely to adhere to their prescribed treatment regimens when they involve simple, oral administration compared to the logistical challenges and discomfort associated with IV treatments. Improved adherence can lead to better clinical outcomes, as consistent medication intake is crucial for the efficacy of cancer therapies. Additionally, oral drugs often have more favorable side effect profiles compared to some traditional chemotherapies. Targeted oral therapies, such as PARP inhibitors used in ovarian cancer treatment, are designed to act on specific molecular pathways involved in cancer progression, minimizing collateral damage to healthy cells. This targeted approach can result in fewer and less severe side effects, making treatment more tolerable for patients.
The development of oral cancer drugs is also driven by advances in pharmaceutical technology and research. The ability to formulate effective oral therapies that maintain their potency and bioavailability within the body is a significant scientific achievement. As research continues to uncover the molecular mechanisms of ovarian cancer, more oral drugs are being developed that target these specific pathways, providing new options for personalized medicine.
Restraints
- High Cost
-
Lack of Skilled Professionals- This shortage encompasses various roles essential to the effective management and treatment of ovarian cancer, including oncologists, specialized surgeons, radiologists, pathologists, and oncology nurses. One of the primary challenges is the insufficient number of oncologists who are trained specifically in gynecologic cancers. These specialists are crucial for diagnosing ovarian cancer accurately and formulating appropriate treatment plans. The complexity of ovarian cancer, which often presents at advanced stages with nonspecific symptoms, requires a high level of expertise to distinguish it from other conditions and to stage the disease accurately. A dearth of such experts can lead to misdiagnosis or delays in diagnosis, which can significantly affect patient outcomes.
Specialized surgeons are also in short supply. Surgical intervention is often the first line of treatment for ovarian cancer, especially in early stages. Procedures such as hysterectomy and oophorectomy, as well as more complex debulking surgeries, require surgeons with specific training and experience in gynecologic oncology. The effectiveness of these surgeries directly correlates with the surgeon's skill, impacting the success of subsequent treatments like chemotherapy or targeted therapy. A lack of experienced surgeons can result in suboptimal surgical outcomes, increasing the likelihood of cancer recurrence and reducing overall survival rates.
Radiologists and pathologists play a crucial role in the accurate staging and assessment of ovarian cancer through imaging and tissue analysis. Advanced imaging techniques such as MRI, CT, and PET scans are vital for determining the extent of the disease and planning treatment. Similarly, pathologists who specialize in ovarian cancer are needed to analyze biopsy samples and identify specific cancer types and genetic mutations that inform targeted therapy decisions. A shortage of these professionals can hinder precise diagnosis and personalized treatment planning, leading to less effective care.
Opportunities
- Increase in Ovarian Cancer
-
Rising Healthcare Awareness- Public health campaigns, educational programs, and widespread dissemination of information through various media channels play pivotal roles in this heightened awareness. One of the primary benefits of rising healthcare awareness is the promotion of regular screenings and check-ups. Women who are informed about the risk factors and early signs of ovarian cancer, such as abdominal bloating, pelvic pain, and changes in urinary habits, are more likely to seek medical advice promptly. This proactive approach facilitates early detection when the cancer is in a more treatable stage, significantly enhancing the effectiveness of therapeutic interventions. Moreover, healthcare awareness encourages individuals to adopt healthier lifestyles, which can reduce the risk of ovarian cancer. Awareness campaigns often emphasize the importance of maintaining a healthy diet, regular exercise, and avoiding known risk factors such as smoking and obesity. These preventive measures not only lower the incidence of ovarian cancer but also improve overall well-being, thereby reducing the burden on healthcare systems.
The increased awareness also drives demand for cutting-edge diagnostic tools and innovative treatments. As more people become knowledgeable about the availability of advanced medical technologies, there is greater acceptance and utilization of methods such as genetic testing, molecular diagnostics, and personalized medicine. Genetic counseling and testing for BRCA mutations, for example, have become more common, allowing for risk assessment and preventive strategies among high-risk populations. Furthermore, healthcare awareness initiatives often lead to better patient education about treatment options, empowering individuals to make informed decisions regarding their care. Patients who are well-informed about the latest advancements in chemotherapy, targeted therapy, immunotherapy, and surgical techniques are more likely to seek and adhere to effective treatment regimens. This not only improves individual outcomes but also drives market growth as the demand for innovative therapies and pharmaceuticals increases.
Healthcare awareness also fosters a more supportive environment for research and development. Public support and advocacy can lead to increased funding for ovarian cancer research, accelerating the development of new treatments and improving clinical trial participation rates. This, in turn, contributes to the discovery of novel therapies and enhances the overall treatment landscape.
Competitive Landscape Analysis
Key players in Global Ovarian Cancer Market include:
- Mylan N.V.
- Teva Pharmaceutical Industries Ltd.
- Sanofi
- Pfizer Inc.
- GlaxoSmithKline plc
- Novartis AG
- Bayer AG
- Eli Lilly and Company
- Merck & Co., Inc.
- Allergan
- AstraZeneca
- Johnson & Johnson Private Limited
- Cipla Inc.
- Abbott
- AbbVie Inc.
- Merck KGaA
- LEO Pharma A/S
- Bausch Health Companies Inc.
In this report, the profile of each market player provides following information:
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Introduction
- Research Objectives and Assumptions
- Research Methodology
- Abbreviations
- Market Definition & Study Scope
- Executive Summary
- Market Snapshot, By Type
- Market Snapshot, By Cancer Stage
- Market Snapshot, By Diagnostic
- Market Snapshot, By Treatment
- Market Snapshot, By Region
- Global Ovarian Cancer Market Dynamics
- Drivers, Restraints and Opportunities
- Drivers
-
Increase in Elderly Population
-
Rising Demand for Oral Drugs
-
- Restraints
-
High Cost
-
Lack of Skilled Professionals
-
- Opportunities
-
Increase in Ovarian Cancer
-
Rising Healthcare Awareness
-
- Drivers
- PEST Analysis
- Political Analysis
- Economic Analysis
- Social Analysis
- Technological Analysis
- Porter's Analysis
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Threat of New Entrants
- Competitive Rivalry
- Drivers, Restraints and Opportunities
- Market Segmentation
- Global Ovarian Cancer Market, By Type, 2021 - 2031 (USD Million)
- Epithelial Ovarian Tumors
- Ovarian Germ Cell Tumors
- Ovarian Stromal Tumors
- Primary Peritoneal Carcinoma
-
Global Ovarian Cancer Market, By Cancer Stage, 2021 - 2031 (USD Million)
-
Stage I
-
Stage II
-
Stage III
-
Stage IV
-
- Global Ovarian Cancer Market, By Diagnostic, 2021 - 2031 (USD Million)
- Physical Examination
- Biopsy
- Blood Tests
- Human Chorionic Gonadotropin (HCG) Test
- Ultrasound
- MRI
- PET
- CT scans
- Global Ovarian Cancer Market, By Treatment, 2021 - 2031 (USD Million)
- Chemotherapy
- Targeted Therapy
- Radiation Therapy
- Immunotherapy
- Hormonal Therapy
- Surgery
- Global Ovarian Cancer Market, By Geography, 2021 - 2031 (USD Million)
- North America
- United States
- Canada
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Nordic
- Benelux
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia & New Zealand
- South Korea
- ASEAN (Association of South East Asian Countries)
- Rest of Asia Pacific
- Middle East & Africa
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- North America
- Global Ovarian Cancer Market, By Type, 2021 - 2031 (USD Million)
- Competitive Landscape
- Company Profiles
- Mylan N.V.
- Teva Pharmaceutical Industries Ltd.
- Sanofi
- Pfizer Inc.
- GlaxoSmithKline plc
- Novartis AG
- Bayer AG
- Eli Lilly and Company
- Merck & Co., Inc.
- Allergan
- AstraZeneca
- Johnson & Johnson Private Limited
- Cipla Inc.
- Abbott
- AbbVie Inc.
- Merck KGaA
- LEO Pharma A/S
- Bausch Health Companies Inc.
- Company Profiles
- Analyst Views
- Future Outlook of the Market